Cargando…
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and are theref...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434202/ https://www.ncbi.nlm.nih.gov/pubmed/30701699 http://dx.doi.org/10.1002/cam4.1995 |
_version_ | 1783406431757664256 |
---|---|
author | Watanabe, Satomi Yonesaka, Kimio Tanizaki, Junko Nonagase, Yoshikane Takegawa, Naoki Haratani, Koji Kawakami, Hisato Hayashi, Hidetoshi Takeda, Masayuki Tsurutani, Junji Nakagawa, Kazuhiko |
author_facet | Watanabe, Satomi Yonesaka, Kimio Tanizaki, Junko Nonagase, Yoshikane Takegawa, Naoki Haratani, Koji Kawakami, Hisato Hayashi, Hidetoshi Takeda, Masayuki Tsurutani, Junji Nakagawa, Kazuhiko |
author_sort | Watanabe, Satomi |
collection | PubMed |
description | HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and are therefore a target for oncotherapy to treat HER2‐positive breast cancer. The anti‐HER2 antibody pertuzumab and anti‐HER3 antibody patritumab both target this heregulin–HER3‐HER2 complex in different ways. This study examined the anticancer efficacy of dual HER2 and HER3 blockade in trastuzumab‐resistant HER2‐positive breast cancer. HER2‐positive SKBR3 or BT474 cells overexpressing heregulin (SKBR3‐HRG, BT474‐HRG) were used to evaluate the efficacy of trastuzumab, pertuzumab, and patritumab in vitro by performing cell viability, immunoblotting, and clonogenic assays. The effects of these agents were then evaluated in vivo using BT474‐HRG and an intrinsic heregulin‐expressing and HER2‐positive JIMT‐1 xenograft models. SKBR3‐HRG and BT474‐HRG cells lost sensitivity to trastuzumab, which was accompanied by Akt activation. Unexpectedly, trastuzumab in combination with pertuzumab or patritumab also showed limited efficacy toward these cells. In contrast, trastuzumab/pertuzumab/patritumab triple treatment demonstrated potent anticancer efficacy, concomitant with strong repression of Akt. Finally, in heregulin‐expressing BT474‐HRG and JIMT‐1 xenograft models, the addition of pertuzumab and patritumab to trastuzumab also enhanced antitumor efficacy leading to tumor regression. The current study found that triple blockade of HER2 and HER3 using trastuzumab, pertuzumab, and patritumab could overcome resistance to trastuzumab therapy in heregulin‐expressing and HER2‐positive breast cancer, which could be exploited clinically. |
format | Online Article Text |
id | pubmed-6434202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64342022019-04-08 Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer Watanabe, Satomi Yonesaka, Kimio Tanizaki, Junko Nonagase, Yoshikane Takegawa, Naoki Haratani, Koji Kawakami, Hisato Hayashi, Hidetoshi Takeda, Masayuki Tsurutani, Junji Nakagawa, Kazuhiko Cancer Med Cancer Biology HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and are therefore a target for oncotherapy to treat HER2‐positive breast cancer. The anti‐HER2 antibody pertuzumab and anti‐HER3 antibody patritumab both target this heregulin–HER3‐HER2 complex in different ways. This study examined the anticancer efficacy of dual HER2 and HER3 blockade in trastuzumab‐resistant HER2‐positive breast cancer. HER2‐positive SKBR3 or BT474 cells overexpressing heregulin (SKBR3‐HRG, BT474‐HRG) were used to evaluate the efficacy of trastuzumab, pertuzumab, and patritumab in vitro by performing cell viability, immunoblotting, and clonogenic assays. The effects of these agents were then evaluated in vivo using BT474‐HRG and an intrinsic heregulin‐expressing and HER2‐positive JIMT‐1 xenograft models. SKBR3‐HRG and BT474‐HRG cells lost sensitivity to trastuzumab, which was accompanied by Akt activation. Unexpectedly, trastuzumab in combination with pertuzumab or patritumab also showed limited efficacy toward these cells. In contrast, trastuzumab/pertuzumab/patritumab triple treatment demonstrated potent anticancer efficacy, concomitant with strong repression of Akt. Finally, in heregulin‐expressing BT474‐HRG and JIMT‐1 xenograft models, the addition of pertuzumab and patritumab to trastuzumab also enhanced antitumor efficacy leading to tumor regression. The current study found that triple blockade of HER2 and HER3 using trastuzumab, pertuzumab, and patritumab could overcome resistance to trastuzumab therapy in heregulin‐expressing and HER2‐positive breast cancer, which could be exploited clinically. John Wiley and Sons Inc. 2019-01-31 /pmc/articles/PMC6434202/ /pubmed/30701699 http://dx.doi.org/10.1002/cam4.1995 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Biology Watanabe, Satomi Yonesaka, Kimio Tanizaki, Junko Nonagase, Yoshikane Takegawa, Naoki Haratani, Koji Kawakami, Hisato Hayashi, Hidetoshi Takeda, Masayuki Tsurutani, Junji Nakagawa, Kazuhiko Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title | Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title_full | Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title_fullStr | Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title_full_unstemmed | Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title_short | Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer |
title_sort | targeting of the her2/her3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in her2‐positive breast cancer |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434202/ https://www.ncbi.nlm.nih.gov/pubmed/30701699 http://dx.doi.org/10.1002/cam4.1995 |
work_keys_str_mv | AT watanabesatomi targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT yonesakakimio targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT tanizakijunko targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT nonagaseyoshikane targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT takegawanaoki targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT haratanikoji targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT kawakamihisato targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT hayashihidetoshi targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT takedamasayuki targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT tsurutanijunji targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer AT nakagawakazuhiko targetingoftheher2her3signalingaxisovercomesligandmediatedresistancetotrastuzumabinher2positivebreastcancer |